Fig. 1 · Structure
Documents & Downloads
Darizmetinib
MAP2K Inhibitor
Darizmetinib is a potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4). By enhancing the MKK7 and JNK1 signaling pathways, it activates the transcription factors ATF2 and ELK1, contributing to increased cell proliferation and liver regeneration. This compound shows potential in research focused on preventing liver failure following extensive oncological liver resections or the transplantation of small liver grafts.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2369583-33-3 |
| Applications | MAP2K Inhibitor |
| Formula | C21H17F2N5O3S |
| Molecular Weight | 457.45 |
| Synonyms | HRX-0215 |
| SMILES | O=C(C1=CC=C(C(NS(=O)(CCC)=O)=C1F)F)C2=NNC3=NC=C(C4=CC=NC=C4)C=C32 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.